Literature DB >> 20577115

Psychometric evaluation of the Glaucoma Symptom Identifier.

John G Walt1, Regina Rendas-Baum, Mark Kosinski, Vaishali Patel.   

Abstract

OBJECTIVE: To evaluate the psychometric properties of the Glaucoma Symptom Identifier (GSI), a tool designed to assess multiple possible glaucoma symptoms and their impact on quality of life in clinical practice. We sought to address the need for better methods to assess visual function related to quality of life of glaucoma patients with a tool to show to both physicians and their patients that glaucoma is not an asymptomatic disease. The development process was to provide comprehensive assessment in 1 page of the impact of glaucoma on patients' quality of life by including an exhaustive list of unique and nonredundant items.
DESIGN: Cross-sectional online survey. PARTICIPANTS: Seven hundred and eighteen individuals with a self-reported diagnosis of glaucoma, who were at least 40 years of age.
METHODS: The impact of glaucoma was assessed by asking study participants the degree of difficulty they experience on a number of tasks. Item response theory was used to psychometrically evaluate the GSI. Scores on the GSI and the SF-12, a generic quality-of-life instrument, were compared. MAIN OUTCOME MEASURES: Items in the GSI were categorized in terms of their ability to capture glaucoma impact on quality of life across the population range of subjects from mild-to-severe glaucoma severity.
RESULTS: The GSI showed good reliability, and convergent and discriminant validity. Items in the GSI captured glaucoma impact on quality of life over an adequate range of disease severity. Potential improvements to the existing questionnaire were identified using item response theory modeling results and respondents' feedback on the survey.
CONCLUSIONS: Our findings suggest that the GSI is a psychometrically valid tool, adequate for glaucoma patients' self-administration within a clinician's routine practice to help both the patient and physician assess the patient's current and potential future symptoms of glaucoma.

Entities:  

Mesh:

Year:  2011        PMID: 20577115     DOI: 10.1097/IJG.0b013e3181e07970

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

Review 1.  Patient-reported outcomes (PRO's) in glaucoma: a systematic review.

Authors:  S Vandenbroeck; S De Geest; T Zeyen; I Stalmans; F Dobbels
Journal:  Eye (Lond)       Date:  2011-03-18       Impact factor: 3.775

2.  Development of an 18-Item Measure of Symptom Burden in Patients With Glaucoma From the Collaborative Initial Glaucoma Treatment Study's Symptom and Health Problem Checklist.

Authors:  David C Musch; Michelle E Tarver; Matt J Goren; Nancy K Janz
Journal:  JAMA Ophthalmol       Date:  2017-12-01       Impact factor: 7.389

Review 3.  A Review of Studies of the Association of Vision-Related Quality of Life with Measures of Visual Function and Structure in Patients with Glaucoma in the United States.

Authors:  Naira Khachatryan; Maxwell Pistilli; Maureen G Maguire; Angela Y Chang; Marissa R Samuels; Kristen Mulvihill; Rebecca J Salowe; Joan M O'Brien
Journal:  Ophthalmic Epidemiol       Date:  2021-02-03

4.  The development of a glaucoma-specific health-related quality of life item bank supporting a novel computerized adaptive testing system in Asia.

Authors:  Eva K Fenwick; Belicia Lim; Ryan E K Man; Mani Baskaran; Monisha E Nongpiur; Chelvin C A Sng; Jayant V Iyer; Rahat Husain; Shamira A Perera; Tina T Wong; Jin Rong Low; Olivia Huang Shimin; Katherine Lun; Tin Aung; Ecosse L Lamoureux
Journal:  J Patient Rep Outcomes       Date:  2022-10-11

Review 5.  Quality of Life in Glaucoma: A Review of the Literature.

Authors:  Luciano Quaranta; Ivano Riva; Chiara Gerardi; Francesco Oddone; Irene Floriani; Anastasios G P Konstas
Journal:  Adv Ther       Date:  2016-04-30       Impact factor: 3.845

6.  Usage of glaucoma-specific patient-reported outcome measures (PROMs) in the Singapore context: a qualitative scoping exercise.

Authors:  Owen Kim Hee; Zheng-Xian Thng; Hong-Yuan Zhu; Ecosse Luc Lamoureux
Journal:  BMC Ophthalmol       Date:  2018-08-14       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.